Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Recurrence 2Neoplasm Metastasis 2Delirium 2

Interventions

Cyclophosphamide 49fludarabine 36Dexamethasone 35venetoclax 29pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Carboplatin 8Bortezomib 8obinutuzumab 7Immunotherapy, Adoptive 7Bevacizumab 7zanubrutinib 6ruxolitinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Haloperidol × 1 year × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡